Placeholder Banner

BIO Comments on FDA Draft Guidance on Adaptive Designs for Clinical Trials of Drugs and Biologics

November 28, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Adaptive Designs for Clinical Trials of Drugs and Biologics: Draft Guidance for Industry, which provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications on the appropriate use of adaptive designs for clinical trials.

BIO says this important draft guidance will help companies use adaptive trial designs to provide evidence of the effectiveness and safety of a drug or biologic. BIO suggests additional information to include in the guidance as well as how to clarify the guidance.

Download Full Comments Below
BIO Comment Letter Adaptive Trials 11-28-18
Read full comment letter below
Discover More
The undersigned food, agriculture, and seafood trade associations respectfully urge the expeditious nomination of the Chief Agricultural Negotiator at the Office of the U.S. Trade Representative. America’s farmers, ranchers, processors, exporters…
The undersigned trade associations and private sector organizations write to express our strong support for the Endless Frontier Act, sponsored by Senate Majority Chuck Schumer (D-NY) and Senator Todd Young (R-IN), which would provide much needed,…
Dr. Michelle McMurry-Heath, along with a group of business and policy leaders, sends an open letter to President Biden urging him "to demonstrate decisive U.S. leadership" to combat COVID-19 in Latin America, Europe, Asia, and Africa…